IL308132A - Methods of treatment of autoimmune disorders using ilt7 binding proteins - Google Patents

Methods of treatment of autoimmune disorders using ilt7 binding proteins

Info

Publication number
IL308132A
IL308132A IL308132A IL30813223A IL308132A IL 308132 A IL308132 A IL 308132A IL 308132 A IL308132 A IL 308132A IL 30813223 A IL30813223 A IL 30813223A IL 308132 A IL308132 A IL 308132A
Authority
IL
Israel
Prior art keywords
weeks
ilt7
binding protein
subject
effective amount
Prior art date
Application number
IL308132A
Other languages
English (en)
Hebrew (he)
Inventor
William Rees
Gabor Illei
Li Yan
Jorn Drappa
John Ratchford
Edward Hammond
Original Assignee
Viela Bio Inc
William Rees
Gabor Illei
Li Yan
Jorn Drappa
John Ratchford
Edward Hammond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc, William Rees, Gabor Illei, Li Yan, Jorn Drappa, John Ratchford, Edward Hammond filed Critical Viela Bio Inc
Publication of IL308132A publication Critical patent/IL308132A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL308132A 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins IL308132A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163183886P 2021-05-04 2021-05-04
US202163197789P 2021-06-07 2021-06-07
US202163242768P 2021-09-10 2021-09-10
US202163249953P 2021-09-29 2021-09-29
US202263326424P 2022-04-01 2022-04-01
PCT/US2022/027620 WO2022235758A1 (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Publications (1)

Publication Number Publication Date
IL308132A true IL308132A (en) 2023-12-01

Family

ID=82021082

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308132A IL308132A (en) 2021-05-04 2022-05-04 Methods of treatment of autoimmune disorders using ilt7 binding proteins

Country Status (10)

Country Link
US (1) US20240287176A1 (https=)
EP (1) EP4333877A1 (https=)
JP (1) JP2024516698A (https=)
KR (1) KR20240004451A (https=)
AU (1) AU2022270101A1 (https=)
BR (1) BR112023023036A2 (https=)
CA (1) CA3217278A1 (https=)
IL (1) IL308132A (https=)
MX (1) MX2023013015A (https=)
WO (1) WO2022235758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
AR130042A1 (es) * 2022-07-27 2024-10-30 Viela Bio Inc Formulaciones que comprenden una proteína de unión al transcripto 7 similar a inmunoglobulina (ilt7)
EP4593823A1 (en) * 2022-09-30 2025-08-06 Abbvie Inc. Methods of treating hidradenitis suppurativa
WO2024126431A1 (en) * 2022-12-12 2024-06-20 Horizon Therapeutics Ireland Dac Anti-ilt7 binding agents for the treatment and prevention of myositis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ616992A (en) * 2005-12-20 2015-07-31 Sbi Biotech Co Ltd Anti-ilt7 antibody
US20110311558A1 (en) * 2008-12-01 2011-12-22 The Board Of Regents Of The University Of Texas System Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
CA2772921A1 (en) * 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
AU2017231833B2 (en) 2016-03-10 2024-03-14 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
IL293572A (en) 2019-12-06 2022-08-01 Viela Bio Inc Treatment methods using ilt7 binding proteins

Also Published As

Publication number Publication date
BR112023023036A2 (pt) 2024-01-23
JP2024516698A (ja) 2024-04-16
WO2022235758A1 (en) 2022-11-10
MX2023013015A (es) 2023-11-15
EP4333877A1 (en) 2024-03-13
AU2022270101A1 (en) 2023-10-05
KR20240004451A (ko) 2024-01-11
US20240287176A1 (en) 2024-08-29
CA3217278A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
IL308132A (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
Del Prato et al. The incretin/glucagon system as a target for pharmacotherapy of obesity
JP4817495B2 (ja) 外因性カンナビノイドでの痛みの制御
WO2007145941A8 (en) Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
JP2010159307A (ja) レセプターの脱感作の予防
IL266674B2 (en) Compositions, devices and methods of using intranasal nalmefene and dodecyl maltoside for treatment of opioid overdose
US5432176A (en) Method of retarding the progression of chronic renal failure
JPH0371413B2 (https=)
CN105228622B (zh) 用于治疗多发性硬化的PPARγ激动剂
DE69927705T2 (de) Verwendung von acetylcholinesterase inhibitoren zur modulierung der hypothalamus-hypophysen-gonadenachse
AU2020203165A1 (en) Methods of treating depression using NMDA modulators
IL314896A (en) Methods of use of anti-trem2 antibodies
JP2009532399A5 (https=)
JP2020510028A5 (https=)
WO2022131919A8 (en) Acth in the treatment of an adrenocorticotropic hormone responsive pediatric disorder
CN101039674A (zh) 河豚毒素及其衍生物用于治疗中枢神经源性神经痛
US20110275807A1 (en) Application of Evodiamine in preparing medicaments for Alzheimer's disease
Gonzales et al. A demonstration that 5-hydroxytryptamine administered peripherally can affect sexual behavior in male rats
EP1645270B1 (en) Control of pain with ANANDAMIDE
CN1486178A (zh) 组胺受体拮抗剂
CN108014337B (zh) 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物
JP2003522792A (ja) 薬剤調製用化合物の用途
Schäfer et al. Combination treatment for chronic hepatitis C with interferon-alpha and ribavirin in psychiatric patients and drug addicts compared to controls
Brotchie et al. Anti-parkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors
NZ763815B2 (en) Methods of using and compositions containing dulaglutide